We use cookies to give you the best possible experience on our website.

Access to the life science market can be a headache for multinational pharma and medical device companies, let alone small-medium sized enterprises (SMEs). SMEs can face significant challenges to introduce new and innovative products into the health and social care market.

The Innovation Nexus provides a single point of access for SMEs in the life science sector to a network of specialist support within Greater Manchester. 

The Innovation Nexus is a gateway to a holistic business growth support offering, focused on the specialist needs of life science SMEs, delivered through a coherent support strategy and an all-inclusive approach to helping businesses develop their growth strategies. 

The aim of the Innovation Nexus is to deliver long-term health and wealth benefits to Greater Manchester through investment, innovation, education and business growth, ultimately improving the health and wellbeing of the Greater Manchester population (and beyond). 

 

INDUSTRY PARTNERSHIP WILL BE A KEY COMPONENT OF HOW HEALTH SYSTEMS WILL IMPROVE HEALTH OUTCOMES FOR THE POPULATIONS THEY SERVE

The challenge for healthcare businesses

Companies, especially SMEs, can face significant challenges to introduce their new and innovative products into the NHS. The complexity of public procurement, patient safety and a risk averse culture across multiple organisations can be daunting. The Innovation Nexus aims to provide a single source of resource that can help companies, particularly SMEs, understand the steps that need to be taken to support their business planning and engage with the NHS more easily, thus progressing the adoption of their innovation at pace and with fewer unanticipated obstacles.

How can the Innovation Nexus help?

Help with navigating NHS procurement

Information about funding and investment

Help with setting up a trial of your innovation

Information on science parks and office locations in the GM AHSN footprint

Connections to organisations that can help you progress your innovation

Speak directly to a GM AHSN advisor with NHS expertise

Latest news Latest news

Back

NIHR Child Prosthetics Industry Collaboration Survey

On the 20th September 2016 the Department of Health announced a total of £1.5M funding for child prosthetic research and technology. The national Child Prosthetics Research Collaboration will bring together clinicians, academics and industry partners so that innovations and research into child prosthetics can be brought to the NHS more quickly and to greater scale. It is to be led by Sheffield-based organisation NIHR Devices for Dignity Healthcare Technology Co-operative (HTC).

Click here for further details.

The focus of this research is specific to upper and lower limb prostheses. 

The purpose of this survey is to identify the needs from within the prosthetic industry in order to stimulate new research and collaborations, accelerate new developments and to raise the profile of the prosthetics community.  This work will focus on understanding not only the current and future industry needs/requirements, but also current areas of excellence and barriers to implementation.  

This research is being carried out to help influence future funding calls with identified unmet needs and will seek to select companies/organisations to the Child Prosthetics Programme.

Find out more and complete the survey here.


Bespoke industry support from NHS experts

If you are a business with an innovative product or service that you believe has the potential to benefit the healthcare market, the Innovation Nexus is your gateway to access a network of specialist advice and support.

Find out more about STEP INto Healthcare - an intensive support programme for life science SMEs working in Greater Manchester

Information and guidance

Access information and guidance on a range of topics related to working with and selling to the NHS, and find clear signposts to organisations that can help you achieve your goals.

Are you an innovator in the NHS or academia?

Read more here >>

Subscribe to our mailing list

* indicates required